A Phase 3 interventional study of Treprostinil sodium in Non-operable Chronic Thromboembolic Pulmonary Hypertension, sponsored by SciPharm SàRL. Completed at 6 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2022-06-07.
Sponsored by SciPharm SàRL · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 10th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2009, is one of 15 in phase 3, and was the 17th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Liquidia Technologies, Inc. · Sites in United States, Australia, Austria and 9 more countries
Ages 18–80
Magdi H. Yacoub · Sites in Egypt
Ages 18+
University of California, San Diego
Ages 18+
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 17 · Phase 4 9
First in 1998; this study’s year is marked. 4 started in 2009.
This study's enrollment of 105 is above the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 32 across the 37 interventional studies. Of the 29 that completed or were terminated, 19 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with SciPharm SàRL as lead sponsor.
SciPharm SàRL has 1 study filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
1 of the studies testing treprostinil in Hypertension, Pulmonary that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116681University of California, San DiegoEffects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension | 2027-07-01 |
Add it to your calendar (.ics) → With an account.
Among the 38 studies testing treprostinil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine the effect on six-minute walking test (6MWT) distance after 24 weeks treatment with subcutaneous (SC) Treprostinil Sodium in patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension.
Chronic thromboembolic pulmonary hypertension (CTEPH) is characterized by non-resolving organized thromboembolic obstructing the pulmonary vascular bed. These thrombi are resistant to thrombolytic therapy and chronic plasmatic anticoagulation. An increase in pulmonary vascular resistance (PVR), right ventricular overload, and eventually right ventricular failure ensue.
The treatment of choice for CTEPH is pulmonary endarterectomy (PEA), providing a potential cure for the disease. However, about 50 % of patients are not candidates for surgery, mainly because of distal location of thromboemboli. Despite recent advances in the treatment of pulmonary arterial hypertension (PAH), medical treatments have not been recommended for inoperable CTEPH, because of the concept that a predominantly major vessel obstructive arteriopathy would not be suitable for vasodilators. Furthermore, a major drawback of i.v. prostacyclin therapy is the need for a permanent central venous access that increases the risk of infection (0.22-0.68 per patient per year), thrombosis and new major vessel thromboembolism.
Subject must have a current diagnosis of CTEPH, as defined by the following criteria:
Subject must have CTEPH classified as severe, as defined by the following criteria:
The subject must not be suitable to undergo a PEA and is therefore defined as non-operable, due to at least one of the following reasons:
PVR > 1500 dynes.s.cm-5 Age Comorbidity No functional lung parenchyma
Exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm I (low dose): Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and was kept stable for another 12 weeks. Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3. This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.
Drug: Treprostinil sodium
Subject was treated with a low dose of Treprostinil sodium. Dose was escalated to an approximate target dose of 3 ng/kg/min after the first 12 weeks and kept stable for another 12 weeks. Due to the predefined infusion rate setting schedule an interim dose of up to 6 ng/kg/min could be reached for few days at the end of the phases 1,2 and 3. This depended on the patient's exact weight and is caused by the limited infusion rate setting possibility of the infusion pump.
Drug: Treprostinil sodium
Change in 6-minute Walk Test Distance After 24 Weeks
To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits: * baseline (day 1) * Visit 6 (day 168) In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.
Time frame: Baseline and 24 weeks
Number of Participants With Clinical Worsening
Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension. Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.
Time frame: 12 weeks and 24 weeks
Effect on Maximal Borg Score During 6-minutes Walk Test
The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to \> 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); \>10 MAXIMUM). As can be seen with the scale, the higher scale values represent a worse outcome. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.
Time frame: Baseline and 24 weeks
Change in WHO/NYHA (World Health Organization - New York Heart Association) Functional Class
Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
Time frame: Baseline and 24 weeks
Effect on Quality of Life by the MINNESOTA Questionnaire
This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.
Time frame: Baseline and 24 weeks
Effect on N-terminal Pro-BNP Levels
baseline values, assessment after 12 and 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.
Time frame: Baseline and 24 weeks
Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance)
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Time frame: Baseline and 24 weeks
Effect on Hemodynamic Parameter (CI - Cardiac Index)
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Time frame: Baseline and 24 weeks
Effect on Hemodynamic Parameter (CO - Cardiac Output)
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Time frame: Baseline and 24 weeks
Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure)
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.
Time frame: Baseline and 24 weeks
Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure)
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
Time frame: Baseline and 24 weeks
Effect on Signs & Symptoms of the CTEPH
baseline values, assessment after 24 weeks
Time frame: Baseline and 24 weeks
| Milestone | Treprostinil Sodium High Dose (~30ng/kg/Min) | Treprostinil Sodium Low Dose (~3ng/kg/Min) |
|---|---|---|
| Started | 53 | 52 |
| Completed | 45 | 46 |
| Not completed | 8 | 6 |
To determine the effect of subcutaneous Treprostinil sodium on 6-minute walk test distance after 24 weeks in patients with severe non-operable chronic thromboembolic pulmonary hypertension severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension Time frame of the 6-minute walk test: The 6-minute walk test was conducted at the following visits: * baseline (day 1) * Visit 6 (day 168) In case of missing values, Last-Observation-Carried-Forward imputation method was used. In such cases values documented at Visit 4 (day84) were used.
| m | High Dose | Low Dose |
|---|---|---|
| Change in 6-minute Walk Test Distance After 24 Weeks | 45.43 ± 71.29 | 3.83 ± 56.21 |
Clinical worsening defined as a decrease of 6-minute walk test distance of more than 20% from baseline due to Chronic Thromboembolic Pulmonary Hypertension, decrease of New York Heart Association functional class, hospitalization with the requirement for additional Pulmonary Hypertension specific treatment and/or death due to worsening Chronic Thromboembolic Pulmonary Hypertension. Clinical Worsening was assessed after 12 weeks and 24 weeks, participants experiencing clinical worsening at any time-point are reported.
| Participants | High Dose | Low Dose |
|---|---|---|
| Number of Participants With Clinical Worsening | 7 | 12 |
The Borg scale was used for rating of dyspnea during 6-minutes walk test. The scale is defined from 0 to \> 10 (upper bound) (0 = NOTHING AT ALL; 0.5 = VERY VERY SLIGHT (just noticeable); 1 = VERY SLIGHT; 2 = SLIGHT; 3 = MODERATE; 4 = SOMEWHAT SEVERE; 5 = SEVERE; 6-9 = VERY SEVERE; 10 = VERY VERY SEVERE (almost maximum); \>10 MAXIMUM). As can be seen with the scale, the higher scale values represent a worse outcome. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 48 patients in low dose group.
| units on a scale | High Dose | Low Dose |
|---|---|---|
| Effect on Maximal Borg Score During 6-minutes Walk Test | -0.44 ± 2.21 | -0.13 ± 2.43 |
Class I - Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain or near syncope. Class II - Patients with pulmonary hypertension resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III - Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes undue dyspnea or fatigue, chest pain or near syncope Class IV - Patients with pulmonary hypertension in the inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may even be present at rest. Discomfort is increased by any physical activity.
| Participants | High Dose | Low Dose |
|---|---|---|
| Improved | 27 | 9 |
| No change | 22 | 36 |
| Worse | 2 | 3 |
| Not done | 2 | 4 |
This questionnaire is composed of 21 questions relating to limitations in lifestyle associated with Heart Failure. Respondents use a 5-point scale that ranges from 0 (none) to 5 (too much), with a score of 0 representing no limitation and a score of 5 representing maximum limitation. The change in individual score sum was evaluated and is displayed in the results, with a possible range of 0-105. Higher values indicate more limitations in Quality of Life. As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 50 patients randomized to high dose group and 46 patients in low dose group.
| units on a scale | High Dose | Low Dose |
|---|---|---|
| Effect on Quality of Life by the MINNESOTA Questionnaire | -6.36 ± 22.9 | -4.63 ± 19.34 |
baseline values, assessment after 12 and 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 46 patients randomized to high dose group and 46 patients in low dose group.
| percentage change to baseline | High Dose | Low Dose |
|---|---|---|
| Effect on N-terminal Pro-BNP Levels | 0.84 ± 63.32 | 41.68 ± 104.2 |
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
| dyn.s.cm^-5 | High Dose | Low Dose |
|---|---|---|
| Effect on Hemodynamic Parameter (PVR - Pulmonary Vascular Resistance) | -214.23 ± 324.28 | 72.96 ± 284.95 |
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
| L/min/m2 | High Dose | Low Dose |
|---|---|---|
| Effect on Hemodynamic Parameter (CI - Cardiac Index) | 0.42 ± 0.9 | -0.16 ± 0.54 |
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
| L/min | High Dose | Low Dose |
|---|---|---|
| Effect on Hemodynamic Parameter (CO - Cardiac Output) | 0.63 ± 1.47 | -0.22 ± 1.06 |
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 47 patients randomized to high dose group and 47 patients in low dose group.
| mmHg | High Dose | Low Dose |
|---|---|---|
| Effect on Hemodynamic Parameter (mPAP - Mean Pulmonary Arterial Pressure) | -3.36 ± 8.04 | -0.4 ± 6.87 |
baseline values, assessment after 24 weeks As no imputation rule applied only full-data sets were evaluated. Complete data sets were available for 48 patients randomized to high dose group and 47 patients in low dose group.
| mmHg | High Dose | Low Dose |
|---|---|---|
| Effect on Hemodynamic Parameter (mRap - Mean Right Atrial Pressure) | 0.65 ± 5.08 | 2.87 ± 6.82 |
baseline values, assessment after 24 weeks
| participants | High Dose | Low Dose |
|---|---|---|
| Ascites : Baseline | 2 | 3 |
| Ascites : Week 24 | 1 | 3 |
| Nausea/Vomiting : Baseline | 4 | 9 |
| Nausea/Vomiting : Week 24 | 5 | 9 |
| Chest pain : Baseline | 13 | 11 |
| Chest pain : Week 24 | 8 | 3 |
| Orthopnoea : Baseline | 9 | 9 |
| Orthopnoea : Week 24 | 3 | 5 |
| Dizziness : Baseline | 25 | 21 |
| Dizziness : Week 24 | 11 | 10 |
| Palpitations : Baseline | 19 | 18 |
| Palpitations : Week 24 | 9 | 11 |
| Dyspnoea at rest : Baseline | 7 | 10 |
| Dyspnoea at rest : Week 24 | 3 | 10 |
| Paroxysmal nocturnal dyspnoea : Baseline | 7 | 1 |
| Paroxysmal nocturnal dyspnoea : Week 24 | 4 | 3 |
| Dyspnoea on exertion : Baseline | 53 | 51 |
| Dyspnoea on exertion : Week 24 | 46 | 43 |
| Syncope : Baseline | 3 | 6 |
| Syncope : Week 24 | 1 | 2 |
| Fatigue : Baseline | 33 | 37 |
| Fatigue : Week 24 | 26 | 27 |
| Thirst : Baseline | 12 | 21 |
| Thirst : Week 24 | 12 | 13 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose | 2/53 (3.8%) | 9/53 (17%) | 53/53 (100%) |
| Low Dose | 1/52 (1.9%) | 10/52 (19.2%) | 51/52 (98.1%) |
| Event | High Dose | Low Dose |
|---|---|---|
| Right ventricular failureCardiac disorders | 6/53 | 1/52 |
| Cardiac failureCardiac disorders | 2/53 | 1/52 |
| DyspneaCardiac disorders | 0/53 | 1/52 |
| SyncopeCardiac disorders | 0/53 | 1/52 |
| DiarrhoeaGastrointestinal disorders | 0/53 | 1/52 |
| NauseaGastrointestinal disorders | 0/53 | 1/52 |
| Incarcerated herniaGeneral disorders | 0/53 | 1/52 |
| AppendicitisInfections and infestations | 0/53 | 1/52 |
| Escherichia bacteraemiaInfections and infestations | 0/53 | 1/52 |
| HypokalaemiaMetabolism and nutrition disorders | 0/53 | 1/52 |
| Event | High Dose | Low Dose |
|---|---|---|
| Infusion site painGeneral disorders | 39/53 | 42/52 |
| DiarrhoeaGastrointestinal disorders | 33/53 | 12/52 |
| Infusion site reactionsGeneral disorders | 25/53 | 24/52 |
| HeadacheNervous system disorders | 12/53 | 4/52 |
| Pain in extremitiesMusculoskeletal and connective tissue disorders | 11/53 | 1/52 |
| Oedema peripheralCardiac disorders | 7/53 | 10/52 |
| NasopharyngitisInfections and infestations | 4/53 | 10/52 |
| Worsening of Pulmonary HypertensionVascular disorders | 3/53 | 8/52 |
| Decreased appetiteGeneral disorders | 7/53 | 0/52 |
| HypokalaemiaMetabolism and nutrition disorders | 4/53 | 5/52 |
| Age, Categorical(Participants) | High Dose | Low Dose | Total |
|---|---|---|---|
| <=18 years | 0 | 1 | 1 |
| Between 18 and 65 years | 15 | 26 | 41 |
| >=65 years | 38 | 25 | 63 |
| Age, Continuous(years) | High Dose | Low Dose | Total |
|---|---|---|---|
| Mean | 68.06 ± 11.16 | 60.58 ± 14.59 | 64.35 ± 13.44 |
| Sex: Female, Male(Participants) | High Dose | Low Dose | Total |
|---|---|---|---|
| Female | 19 | 30 | 49 |
| Male | 34 | 22 | 56 |
| Region of Enrollment(participants) | High Dose | Low Dose | Total |
|---|---|---|---|
| Austria | 28 | 26 | 54 |
| Czechia | 17 | 17 | 34 |
| Poland | 8 | 8 | 16 |
| Germany | 0 | 1 | 1 |
The record gives a start of Mar 2009, a primary completion of Nov 2016 and a completion of Apr 2021. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2019, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil